Fig. 6
From: Circular HER2 RNA positive triple negative breast cancer is sensitive to Pertuzumab
HER2–103 expressing TNBC are sensitive to Pertuzumab. a Illustration of circ-HER2 mechanisms in TNBC. Circ-HER2 encoded HER2–103 in TNBC cells. HER2–103 induced EGFR/EGFR homodimer and/or EGFR/HER3 heterodimer, activated downstream PI3K-AKT pathway and promoted tumor proliferation and progression. This oncogenic phenotype induced by HER2–103 can be inhibited by Pertuzumab, which recognize CR I domain of HER2. b Tumor volume of in vivo xenograft implanted with indicated TNBCs and treated with control IgG or Pertuzumab (20 mg/Kg). c Representative IHC staining of pEGFRY1068 and pAKT (Thr308) in each xenograft group as indicated. d Representative lung and representative HE staining of lung metastatic lesions in each xenograft group as indicated, original magnification, × 4, scale bar, 100 μm. The number of metastatic nodules formed in the lungs of mice for each group were shown. Lines show the mean ± SD, ***, p < 0.001; **, p < 0.01; *p < 0.05. Data are representative from at least 2–3 experiments with similar results. N = 5 mice in each in vivo experiment